Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells.

Nature communications·2026

Same author

Lymphatic egress recycles tumor-experienced effector CD8 T cells to sustain immune surveillance.

bioRxiv : the preprint server for biology·2026

Same author

A tumor metabolism-angiogenesis-immune axis governs immunotherapy responses.

bioRxiv : the preprint server for biology·2026

Same author

Peripheral immune-inducer dendritic cells drive early-life allergic inflammation.

Nature·2026

Same author

Chromatin architecture and physical constriction cooperate in phenotype switching and cancer cell dissemination.

bioRxiv : the preprint server for biology·2026

Same author

Transcription factor Etv3 controls the tolerogenic function of dendritic cells.

Science (New York, N.Y.)·2026

Same journal

Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer.

Med (New York, N.Y.)·2026

Same journal

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.

Med (New York, N.Y.)·2026

Same journal

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026

Same journal

Atlas of human brain imaging-derived phenotypes and disease risk.

Med (New York, N.Y.)·2026

Same journal

Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine.

Med (New York, N.Y.)·2026

Same journal

Rethinking parenteral nutrition as supportive therapy for neonatal sepsis.

Med (New York, N.Y.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 22, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Targeting LRG1 boosts immunotherapy.

Amanda W Lund¹, Michele De Palma²

¹The Ronald O. Perelman Department of Dermatology, Department of Pathology, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.

Med (New York, N.Y.)

|May 19, 2022

Summary

This summary is machine-generated.

Inhibiting LRG1 protein stabilizes tumor vasculature, improving drug delivery and immune cell infiltration. This vascular normalization enhances tumor response to cancer therapies.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Experiment Videos

Last Updated: Sep 22, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Area of Science:

Oncology
Cancer Biology
Vascular Biology

Background:

Vascular normalization therapy aims to improve anti-cancer treatment efficacy.
Tumor vasculature is often abnormal, hindering drug delivery and immune cell infiltration.
Identifying optimal targets and treatment strategies for vascular normalization is crucial.

Purpose of the Study:

To investigate the role of LRG1 in tumor vasculature.
To determine if LRG1 inhibition can stabilize tumor-associated vasculature.
To evaluate the impact of LRG1 inhibition on the efficacy of cytotoxic and immune therapies.

Main Methods:

The study by O'Connor et al. focused on LRG1 as a therapeutic target.
Experiments were conducted to assess the effects of LRG1 inhibition on tumor vasculature.
Tumor response to cytotoxic and immune-based treatments was evaluated following LRG1 inhibition.

Main Results:

Inhibition of LRG1 was shown to stabilize tumor-associated vasculature.
Stabilized vasculature facilitated enhanced drug delivery into tumors.
LRG1 inhibition improved tumor response to both cytotoxic and immune therapies.

Conclusions:

LRG1 is a key regulator of tumor vasculature.
Targeting LRG1 represents a promising strategy for vascular normalization therapy.
LRG1 inhibition can enhance the effectiveness of existing cancer treatments.